You take your first few doses of a GLP-1 medication, step on the scale and see almost no difference.
That can feel discouraging—especially after seeing dramatic before-and-after stories online. But body weight is not necessarily the first thing you will notice changing.
For some people, an earlier clue is quieter: they are less hungry between meals, get full with a smaller portion, think about snacks less often or find that a food they normally struggle to resist suddenly feels easier to leave alone.
Those changes make biological sense. Research involving semaglutide and tirzepatide has found effects on appetite, satiety, food cravings and energy intake. They should not, however, be treated as a guarantee that a particular person will go on to lose a particular amount of weight.
Key takeaways
- The first signs a GLP-1 is working may involve appetite rather than body weight. Less hunger, earlier fullness and weaker food cravings have been documented in clinical research.
- There is no universal day when you should suddenly “feel” the medication. People respond differently, and many GLP-1-based treatments are deliberately started at a low dose and increased gradually.
- Nausea is not evidence that the medication is working. Gastrointestinal symptoms are adverse effects, not a treatment goal.
- One week of scale readings is a poor test of treatment success. Contemporary guidance recommends following effectiveness, tolerability and health outcomes over time, with newer GLP-1-based treatments potentially requiring several months for a fair assessment.
- Do not increase your dose simply because you cannot feel an effect yet. Titration schedules are designed partly to reduce gastrointestinal adverse effects.
How to know if a GLP-1 is working
There is no single symptom that confirms a GLP-1 medication is effective. Still, several changes may be worth noticing before you focus exclusively on pounds lost.
You may feel less hungry between meals
GLP-1-based medications influence pathways involved in appetite and food intake. The current Wegovy prescribing information states that semaglutide decreases calorie intake and that its effect on body weight is likely mediated in part through appetite.
Controlled research has likewise found lower hunger with semaglutide. A study of semaglutide 2.4 mg found reduced hunger and prospective food consumption alongside greater fullness and satiety compared with placebo.
You may feel satisfied with less food
Some patients describe reaching the point of “that is enough” sooner than they previously did.
That experience is consistent with research showing increased satiety and fullness with semaglutide. Tirzepatide research has also demonstrated reductions in appetite and food intake.
This does not mean deliberately eating as little as possible. Adequate nutrition remains important during treatment.
Cravings or food preoccupation may become less intense
This may be one of the more meaningful early changes for someone who previously spent a large part of the day thinking about their next meal or snack.
Semaglutide trials have reported improvements in food cravings and control of eating. A 2026 randomized study also found reductions in hunger and food preoccupation at an earlier assessment point, although some subjective appetite differences became less pronounced later in treatment even while energy intake remained lower.
The popular expression “food noise” is useful shorthand for some patients, but it is not itself a formal diagnostic measurement.
Why appetite can change before the scale does
Weight loss is the downstream result of many processes. Appetite and energy intake can change first; body weight then changes over time.
There is another important reason not to judge treatment after only a few injections: dose escalation is gradual by design.
For example, current U.S. labeling starts injectable Wegovy at 0.25 mg weekly for four weeks, followed by stepwise increases. Current Zepbound labeling begins tirzepatide at 2.5 mg weekly for four weeks before increasing to 5 mg, with further increases made no more frequently than every four weeks when appropriate.
In other words, the first month is not necessarily representative of your eventual maintenance-dose experience.
Early signs versus what they actually prove
| What you notice | What it may suggest | What it does not prove |
|---|---|---|
| Less hunger | Appetite-related effects may be occurring | That you will reach a specific weight |
| Fullness after a smaller meal | Satiety may have changed | That your current dose is ideal |
| Fewer cravings | Eating behavior may be changing | That the medication will work indefinitely |
| Smaller spontaneous portions | Calorie intake may be decreasing | That you should deliberately skip meals |
| Nausea | A recognized adverse effect | That the medication is especially effective |
| No immediate scale change | Very little by itself early on | That treatment has failed |
The distinction matters because subjective appetite effects and long-term clinical effectiveness are related concepts, but they are not interchangeable.
What if your GLP-1 is working but you are not losing weight yet?
If you have recently started treatment, appetite changes without much scale movement do not automatically indicate a problem.
You may still be in the titration period, and treatment response varies substantially between individuals. Current obesity-care standards emphasize individualized goals and regular reassessment rather than expecting identical trajectories from everyone.
Historically, clinicians have often used roughly 5% body-weight reduction after three months as a marker of an adequate early response to obesity medication. That benchmark still appears in current guidance. However, a 2026 cardiovascular guideline specifically notes that newer GLP-1-based therapies can continue producing weight loss for much longer and suggests that the therapeutic assessment window may sometimes extend toward six months.
That does not mean waiting six months regardless of circumstances. Significant side effects, problems taking the medication, cost, inadequate response or changes in health may justify earlier review.
What if you do not feel any appetite change at all?
Do not assume that you should take more medication.
A starter dose may produce subtle effects in one person and obvious effects in another. Both semaglutide and tirzepatide labels instruct clinicians to escalate gradually, taking tolerability and treatment response into account.
If weeks pass without the expected progress, the useful questions are not simply “Should I double my dose?” but:
- Am I taking the medication correctly?
- Where am I in the approved titration schedule?
- Has my weight trend changed over several weeks?
- Have my hunger, portions or eating patterns changed?
- Are side effects limiting nutrition or adherence?
- Does my clinician think the dose or treatment plan should change?
Dose changes should be handled with the prescribing clinician rather than improvised at home.
Side effects are not proof that your GLP-1 is working
Nausea, vomiting, diarrhea, constipation and abdominal symptoms are among the commonly reported adverse reactions with semaglutide and tirzepatide weight-management products. They may be particularly relevant during dose escalation.
Feeling sick therefore should not be interpreted as evidence that you have found the “right” dose.
Persistent vomiting or diarrhea can contribute to dehydration. Both current semaglutide and tirzepatide labeling also warn about pancreatitis and gallbladder disease. Persistent or severe abdominal pain—particularly pain that may radiate toward the back—requires prompt medical assessment.
People taking insulin or certain diabetes medications such as sulfonylureas may also have an increased risk of hypoglycemia and may require medication adjustments by their healthcare professional.
What good GLP-1 follow-up should look like
A competent weight-management program should be interested in more than whether you lost three pounds this week.
Current obesity-care recommendations call for ongoing assessment of effectiveness, safety, tolerability, adherence and relevant health outcomes. Early follow-up is particularly useful while doses are being adjusted.
For an online program, useful questions include:
- Who reviews my progress and adjusts my dose?
- How often is follow-up provided during titration?
- What should I do if I experience persistent gastrointestinal symptoms?
- How does the clinician decide whether treatment is working?
- When would the clinician consider changing the dose or medication?
- Who can I contact between scheduled appointments?
- If compounded medication is offered, which pharmacy prepares it?
Compounded drugs are not FDA approved and do not undergo FDA premarket review for safety, effectiveness and quality. Consumers should be particularly cautious of clinics that describe compounded GLP-1 products or compounding pharmacies themselves as “FDA approved.”
The practical takeaway
The first sign your GLP-1 is working may be surprisingly ordinary: lunch satisfies you sooner, the afternoon snack loses some of its pull, or hunger stops dominating the hours between meals.
Those changes are consistent with how GLP-1-based medications can influence appetite and food intake. They are useful observations—but not a substitute for objective follow-up.
The better question is therefore not “Did I lose weight immediately?” It is whether a pattern is developing: appetite changes, improving weight trends, acceptable side effects and progress toward the health goals you and your clinician established.
That takes longer to judge than a single weigh-in.
Frequently asked questions
When does a GLP-1 start working?
There is no universal point when everyone should notice an effect. Pharmacologic effects begin as the medication is taken, but the timing and intensity of noticeable appetite or weight changes vary. Semaglutide and tirzepatide weight-management regimens also use gradual dose escalation, so a person’s experience during the first several weeks may differ substantially from their experience later in treatment.
Is reduced appetite a sign that my GLP-1 is working?
It can be. Clinical studies have found reductions in hunger, appetite and food intake with semaglutide and tirzepatide. However, reduced appetite alone cannot predict exactly how much weight an individual will lose.
Can a GLP-1 be working even if I have not lost weight?
Potentially, particularly during early dose escalation. Appetite and eating behavior may change before substantial weight reduction is visible. Persistent lack of progress later in treatment should nevertheless be reviewed with the prescribing clinician rather than assumed to be normal indefinitely.
Does nausea mean my GLP-1 is working?
No. Nausea is a recognized adverse effect, not a marker of therapeutic success. Effective treatment does not require feeling nauseated.
What should I do if I do not feel anything after my first GLP-1 dose?
Continue the medication according to the prescribed schedule unless your healthcare professional tells you otherwise. Do not increase the dose yourself. Weight-management GLP-1-based medications are commonly titrated over several months to balance response with tolerability.
How long should I give a GLP-1 before deciding it is not working?
There is no single cutoff suitable for everyone. A roughly 5% reduction after three months has historically been used as an early-response benchmark, while newer 2026 guidance recognizes that modern GLP-1-based therapies may warrant assessment over a longer window—potentially toward six months—because dose escalation and continued weight loss take time. The decision should also account for tolerability, adherence, health benefits and treatment burden.
Should I increase my dose if my appetite comes back before my next injection?
Not without discussing it with the prescribing clinician. Dose selection should account for treatment response and tolerability, and approved regimens specify minimum intervals before escalation.
